Bioven could go public in London
Bioven, gestora de un medicamento cubano, podría cotizar en Londres
Intel ID : 227590
| Synopsis |
|
Malaya-based Bioven, a developer of cancer treatment drug discovered in Cuba, could go public in London Stock Exchange, as reported by newspaper Milenio on 27 July 2015. Bioven acquired drug's rights. The treatment showed promising results in its initial phase in the Island. The company has good relations in Cuba.
(content in spanish)
La compañía malaya Bioven, que desarrolla un medicamento contra el cáncer que se descubrió en Cuba, podría comenzar a cotizar en la bolsa de Londres, según ha publicado el diario Milenio en un artículo del 27 de julio de 2015. Bioven compró los derechos de este medicamento contra el cáncer y que demostró ser prometedor en las pruebas de fase inicial en la isla. La compañía comparte buenas relaciones con la isla caribeña. |
| Intel ID | 227590 | |
| Value | ND | |
| Native Currency |
US Dollar (USD)
Exchange Rate:  |
|
| Date |
|
|
| Country | |
|
| Region | ||
| Continent |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Issuer
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.